Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Clinical Pharmacology Study of NS-580 in Healthy Female Subjects
jRCT2071220011Phase 1Completed
- Sponsor
- Nippon Shinyaku
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of friluglanstat in endometriosis, sponsored by Nippon Shinyaku. Primary endpoints: AUC0-t of NS-580 and Cmax of NS-580. Started Jun 2022; status: completed.
02
Drugs
friluglanstat
03
Conditions
endometriosis
Beyond the preview
Go deeper on jRCT2071220011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220011.